Meeting
2013 ASCO Annual Meeting
Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Αnocef phase II trial.
Authors
German Reyes-Botero
Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
German Reyes-Botero , Jerôme Honnorat , Oliver L. Chinot , Luc Taillandier , Isabelle Catry-Thomas , Jerome Barriere , Jean Sebastien Guillamo , Michel Fabbro , Didier Frappaz , Alexandra Benouaich Amiel , Emilie Le Rhun , Chantal Campello , Isabelle Tennevet , François Ghiringhelli , Marie-Laure Tanguy , Karima Mokhtari , Jean-Yves Delattre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2020)
DOI
10.1200/jco.2013.31.15_suppl.2020
Abstract #
2020
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Donna Molaie
Poster
2017 ASCO Annual Meeting
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Phioanh Leia Nghiemphu
Poster
2013 ASCO Annual Meeting
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation.
First Author: Jeffrey J. Raizer
Poster
2013 ASCO Annual Meeting
Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.
First Author: Martin Kelly Nicholas